The document projects growth in the pharmaceutical market based on GDP per capita in developed and developing countries. Several blockbuster drugs will go off patent between 2014-2017, opening opportunities for generic competition in drugs previously produced by Pfizer, Eli Lilly, AstraZeneca, Merck, Novartis and GlaxoSmithKline.